Using liquid biopsies is minimally invasive, fast and easy to perform and provides an excellent solution to study the presence of KRAS mutations in different cancer types like colorectal cancer, pancreatic cancer and non-small cell lung cancer (NSCLC).
Discover the benefits of the Idylla™ ctKRAS Mutation Assay - the easiest solution to implement liquid biopsy testing in your lab.
The Idylla™ ctKRAS Mutation Assay, performed on the Biocartis Idylla™ System, is a sample-to-result real-time PCR assay for the qualitative detection of 21 mutations in codons 12, 13, 59, 61, 117, and 146 of the KRAS gene. The Idylla™ ctKRAS Mutation Assay extracts and amplifies KRAS circulating tumor DNA (ctDNA) from 1 ml of plasma. Fully automated software interpretation and reporting is also integrated, and provides a result in approx. 130 minutes.
Biocartis is recruiting centers for a prospective biomarker study comparing turnaround times of standard of care methods and biomarker testing with Idylla™.
One of the biggest challenges oncology labs face with biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed. For solid biopsies, just one slice of tissue is enough and our plasma-based assays require only 1 ml of plasma.